PubMed

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.

Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O.

Diabetes Care. 2008 Aug;31(8):1510-5. Epub 2008 Apr 28.PMID: 18443195 [PubMed - indexed for MEDLINE]Related articlesFree article

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.PMID: 17593245 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.

Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.

Adv Ther. 2008 Aug;25(8):752-74.PMID: 18704282 [PubMed - indexed for MEDLINE]Related articles

Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.

Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S.

Curr Med Res Opin. 2005 Dec;21(12):2063-71.PMID: 16368057 [PubMed - indexed for MEDLINE]Related articles

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

Curr Med Res Opin. 2007 Mar;23(3):609-22.PMID: 17355742 [PubMed - indexed for MEDLINE]Related articles

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ.

Int J Clin Pharmacol Ther. 2009 Aug;47(8):501-15.PMID: 19640359 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.

Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.

Curr Med Res Opin. 2008 May;24(5):1417-28. Epub 2008 Apr 8.PMID: 18400145 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

CDC Diabetes Cost-effectiveness Group.

JAMA. 2002 May 15;287(19):2542-51.PMID: 12020335 [PubMed - indexed for MEDLINE]Related articlesFree article

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.PMID: 16904047 [PubMed - indexed for MEDLINE]Related articlesFree article

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.PMID: 16904046 [PubMed - indexed for MEDLINE]Related articlesFree article

Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.PMID: 16800162 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.

Brändle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ.

Swiss Med Wkly. 2009 Mar 21;139(11-12):173-84.PMID: 19330561 [PubMed - indexed for MEDLINE]Related articlesFree article

Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.

Roze S, Valentine WJ, Evers T, Palmer AJ.

Curr Med Res Opin. 2006 Jul;22(7):1415-24.PMID: 16834840 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.

Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF, Groleau D.

Curr Med Res Opin. 2009 May;25(5):1273-84.PMID: 19366302 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.

Brändle M, Azoulay M, Greiner RA.

Int J Clin Pharmacol Ther. 2007 Apr;45(4):203-20.PMID: 17474539 [PubMed - indexed for MEDLINE]Related articles

Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.

Grima DT, Thompson MF, Sauriol L.

Pharmacoeconomics. 2007;25(3):253-66.PMID: 17335310 [PubMed - indexed for MEDLINE]Related articles

Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.

Palmer AJ, Sendi PP, Spinas GA.

Schweiz Med Wochenschr. 2000 Jul 11;130(27-28):1034-40.PMID: 10953853 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.

Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.

Can J Clin Pharmacol. 2009 Summer;16(2):e331-45. Epub 2009 Jun 16.PMID: 19531812 [PubMed - indexed for MEDLINE]Related articlesFree article

The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.

[No authors listed]

JAMA. 1998 Nov 25;280(20):1757-63. Erratum in: JAMA 1999 Jan 27;281(4):325. PMID: 9842951 [PubMed - indexed for MEDLINE]Related articlesFree article

Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.

Maetzel A, Ruof J, Covington M, Wolf A.

Pharmacoeconomics. 2003;21(7):501-12.PMID: 12696990 [PubMed - indexed for MEDLINE]Related articles